Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Compare

955 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARQT Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Arcutis

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARQT Stock 12 Month Forecast

Average Price Target

$34.11

▲(19.39% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Arcutis Biotherapeutics in the last 3 months. The average price target is $34.11 with a high forecast of $37.00 and a low forecast of $31.00. The average price target represents a 19.39% change from the last price of $28.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","25":"$25","38":"$38","18.5":"$18.5","31.5":"$31.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.111111111111114,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,18.5,25,31.5,38],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.57,26.44923076923077,27.32846153846154,28.20769230769231,29.086923076923078,29.966153846153848,30.845384615384617,31.724615384615383,32.603846153846156,33.48307692307692,34.362307692307695,35.24153846153846,36.12076923076923,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.57,26.22700854700855,26.884017094017096,27.54102564102564,28.19803418803419,28.855042735042737,29.512051282051285,30.169059829059833,30.826068376068378,31.483076923076926,32.140085470085474,32.79709401709402,33.45410256410257,{"y":34.111111111111114,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.57,25.987692307692306,26.405384615384616,26.823076923076922,27.24076923076923,27.658461538461538,28.076153846153847,28.493846153846153,28.911538461538463,29.32923076923077,29.74692307692308,30.164615384615384,30.582307692307694,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.24,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.75,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.29,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.31,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.57,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$37.00

Average Price Target$34.11

Lowest Price Target$31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Law CFA

Goldman Sachs

$29→$33

Hold

15.51%

Upside

Reiterated

02/27/26

Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (NASDAQ: ARQT), DENTSPLY SIRONA (NASDAQ: XRAY) and Edgewise Therapeutics (NASDAQ: EWTX)

Seamus Fernandez

Guggenheim

$34→$35

Buy

22.51%

Upside

Reiterated

02/26/26

Arcutis Biotherapeutics (ARQT) Receives a Buy from Guggenheim

Tyler Van Buren

TD Cowen

$30→$35

Buy

22.51%

Upside

Reiterated

02/26/26

Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating

Douglas Tsao

H.C. Wainwright

$30→$34

Buy

19.01%

Upside

Reiterated

02/26/26

Arcutis Biotherapeutics price target raised to $34 from $30 at H.C. WainwrightArcutis Biotherapeutics price target raised to $34 from $30 at H.C. Wainwright

Serge Belanger

Needham

$31→$36

Buy

26.01%

Upside

Reiterated

02/26/26

Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target

Judah Frommer

Morgan Stanley

$35

Buy

22.51%

Upside

Reiterated

02/26/26

Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating

Uy Ear

Mizuho Securities

$37

Buy

29.51%

Upside

Reiterated

02/26/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$31

Buy

8.51%

Upside

Reiterated

01/27/26

Jefferies Keeps Their Buy Rating on Arcutis Biotherapeutics (ARQT)

Kambiz Yazdi

BTIG

$31

Buy

8.51%

Upside

Reiterated

01/15/26

BTIG Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Law CFA

Goldman Sachs

$29→$33

Hold

15.51%

Upside

Reiterated

02/27/26

Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (NASDAQ: ARQT), DENTSPLY SIRONA (NASDAQ: XRAY) and Edgewise Therapeutics (NASDAQ: EWTX)

Seamus Fernandez

Guggenheim

$34→$35

Buy

22.51%

Upside

Reiterated

02/26/26

Arcutis Biotherapeutics (ARQT) Receives a Buy from Guggenheim

Tyler Van Buren

TD Cowen

$30→$35

Buy

22.51%

Upside

Reiterated

02/26/26

Arcutis: Strong Zoryve Outperformance, Upgraded 2026 Outlook, and Pipeline Momentum Support Buy Rating

Douglas Tsao

H.C. Wainwright

$30→$34

Buy

19.01%

Upside

Reiterated

02/26/26

Arcutis Biotherapeutics price target raised to $34 from $30 at H.C. WainwrightArcutis Biotherapeutics price target raised to $34 from $30 at H.C. Wainwright

Serge Belanger

Needham

$31→$36

Buy

26.01%

Upside

Reiterated

02/26/26

Arcutis Biotherapeutics: Zoryve’s Outperformance and Strengthening Outlook Support Buy Rating and Higher $36 Target

Judah Frommer

Morgan Stanley

$35

Buy

22.51%

Upside

Reiterated

02/26/26

Arcutis Therapeutics: Commercial Outperformance and Upgraded Zoryve Outlook Support Buy Rating

Uy Ear

Mizuho Securities

$37

Buy

29.51%

Upside

Reiterated

02/26/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$31

Buy

8.51%

Upside

Reiterated

01/27/26

Jefferies Keeps Their Buy Rating on Arcutis Biotherapeutics (ARQT)

Kambiz Yazdi

BTIG

$31

Buy

8.51%

Upside

Reiterated

01/15/26

BTIG Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcutis Biotherapeutics

3 Months

xxx

Success Rate

10/17 ratings generated profit

Average Return

+8.12%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +8.12% per trade.

1 Year

Tyler Van BurenTD Cowen

Success Rate

15/17 ratings generated profit

Average Return

+72.61%

a rating ―

Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +72.61% per trade.

2 Years

xxx

Success Rate

17/17 ratings generated profit

Average Return

+146.96%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +146.96% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARQT Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARQT has received 18 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ARQT average Analyst price target in the past 3 months is 34.11.

Each month's total comprises the sum of three months' worth of ratings.

ARQT Financial Forecast

ARQT Earnings Forecast

Next quarter’s earnings estimate for ARQT is -$0.04 with a range of -$0.13 to $0.06. The previous quarter’s EPS was $0.13. ARQT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ARQT has Performed in-line its overall industry.

ARQT Sales Forecast

Next quarter’s sales forecast for ARQT is $103.08M with a range of $94.30M to $111.00M. The previous quarter’s sales results were $129.50M. ARQT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year ARQT has Performed in-line its overall industry.

ARQT Stock Forecast FAQ

What is ARQT’s average 12-month price target, according to analysts?

Based on analyst ratings, Arcutis Biotherapeutics’s 12-month average price target is 34.11.

What is ARQT’s upside potential, based on the analysts’ average price target?

Arcutis Biotherapeutics has 19.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ARQT a Buy, Sell or Hold?

Arcutis Biotherapeutics has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Arcutis Biotherapeutics’s price target?

The average price target for Arcutis Biotherapeutics is 34.11. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.00 ,the lowest forecast is $31.00. The average price target represents 19.39% Increase from the current price of $28.57.

What do analysts say about Arcutis Biotherapeutics?

Arcutis Biotherapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of ARQT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

ARQT Analyst Ratings

ARQT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Arcutis Biotherapeutics

ARQT Analyst Recommendation Trends

ARQT Financial Forecast

ARQT Earnings Forecast

ARQT Sales Forecast

ARQT Stock Forecast FAQ

Detailed List of Analyst Forecasts